What is Depixus?
Depixus is a pioneering biotechnology firm dedicated to the development of advanced technologies for the rapid, accurate, and cost-effective extraction of genetic and epigenetic information. By focusing on single molecules of DNA and RNA, the company addresses critical bottlenecks in current sequencing methodologies. Its platform is designed to provide high-resolution insights that are essential for modern molecular diagnostics and therapeutic research. With commercial development currently underway, Depixus is effectively bridging the gap between laboratory-scale innovation and industrial-grade application, supported by a team of industry veterans and seasoned angel investors.
How much funding has Depixus raised?
Depixus has raised a total of $35.4M across 1 funding round:
Series A
$35.4M
Series A (2021): $35.4M with participation from Bpifrance, Lansdowne Partners, Casdin Capital, and Arix Bioscience
Key Investors in Depixus
Bpifrance
A French public investment bank that provides credit, guarantees, and equity to support companies across all stages of development, with a strong emphasis on innovation and international expansion.
Lansdowne Partners
A London-based investment management firm established in 1998, focused on delivering superior long-term returns through disciplined capital allocation and strategic partnership.
Arix Bioscience
A global venture capital firm specializing in the life sciences sector, dedicated to building breakthrough biotech companies by providing capital, expertise, and extensive industry networks.
What's next for Depixus?
Looking ahead, the capital secured will be instrumental in scaling Depixus's operational capabilities and expanding its market footprint. The company is expected to prioritize the finalization of its commercial infrastructure, ensuring that its sequencing technologies can be seamlessly integrated into existing clinical and research workflows. As the firm moves deeper into its growth phase, the focus will likely shift toward strategic partnerships and the global distribution of its diagnostic solutions. By maintaining its trajectory of technical excellence, Depixus is poised to become a cornerstone player in the next generation of life sciences infrastructure, potentially redefining the standards for molecular data acquisition.
See full Depixus company page
